A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
Hans J. Hammers,Elizabeth R. Plimack,J. R. Infante,Brian I. Rini,David F. McDermott,Lionel D. Lewis,Martin H. Voss,Padmanee Sharma,Sumanta K. Pal,Albiruni Ryan Abdul Razak,Christian K. Kollmannsberger,D.Y.C. Heng,Jennifer L. Spratlin,B. McHenry,Paul Gagnier,Asim Amin +15 more
Journal ArticleDOI
Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.
Rosalyn A. Juergens,Scott V. Bratman,Ming-Sound Tsao,Scott A. Laurie,M. Sara Kuruvilla,Albiruni Ryan Abdul Razak,Aaron R. Hansen +6 more
TL;DR: Clinical trial data on EGFR-inhibitors in the treatment of squamous cell carcinoma of the lung and head and neck and SCCHN is reviewed, highlighting several key molecules that have shown promise in preclinical studies and clinical trials across multiple cancer sites.
Journal ArticleDOI
INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
Michael Heinrich,Robin L. Jones,Hans Gelderblom,Suzanne George,Patrick Schöffski,Margaret von Mehren,John Zalcberg,Yoon-Koo Kang,Albiruni Ryan Abdul Razak,Jonathan C. Trent,Steven Attia,Axel Le Cesne,Ying Su,Julie Meade,Tao Wang,Matthew L. Sherman,Rodrigo Ruiz-Soto,Jean-Yves Blay,Sebastian Bauer +18 more
TL;DR: The PFS in both arms was longer than PFS achieved by sunitinib in its pivotal phase 3 trial, and the ORR was numerically higher for ripretinib vs sunit inib in the Ex11 ITT (23.9% vs 14.6%; difference 9.3%, 95% CI 0.7, 17.8; nominal P = 0.27).
Journal ArticleDOI
First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
Albiruni Ryan Abdul Razak,Morten Mau Soerensen,Amit Mahipal,Sharon Shacham,Cindy Y. F. Yau,Ulrik Lassen,Dilara McCauley,Jennifer Cooksey,David Shao Peng Tan,Jean-Richard Saint-Martin,Y. Landesman,Gregory R. Pond,Amit M. Oza,Michael Kauffman,Lillian L. Siu,Mansoor Raza Mirza +15 more
TL;DR: In cancers, the majority of tumor suppressor proteins (TSP) are transported out of the nucleus exclusively by Exportin 1 (XPO1/CRM1), rendering these TSPs non-functional.
Journal ArticleDOI
Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214.
Derek J. Jonker,Sebastien J. Hotte,Albiruni Ryan Abdul Razak,Daniel J. Renouf,Brian D. Lichty,John C. Bell,Jean Powers,Caroline J. Breitbach,David F. Stojdl,Kyle B Stephenson,Jonathan L. Bramson,Jeff Hummel,Chantal G Lemay,Jean-Claude Cutz,Julie Wells,Robin Eady,Xiaoqun Sun,Dongsheng Tu,Janet Dancey +18 more
TL;DR: OVs display oncolytic activity and boost adaptive cell immunity and MG1MA3 is a Maraba virus modified to express tumour antigen MAGE-A3, both alone and after immune priming.